3.700USD+6.63%Mkt Cap: 48.21M USDP/E: —Last update: 2026-06-01
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small ce…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap48.21M USD
Enterprise Value34.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.12M USD
Revenue/Share—
Last Price3.700 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.78
PEG—
EV/EBITDA-2.07
EV/Revenue—
P/S—
P/B6.18
EPS (TTM)-1.45
EPS (Forward)-2.02
52W Range
1.11056% of range5.744
52W High5.744 USD
52W Low1.110 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-262.00%
ROA-155.13%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.68M USD
CapEx (TTM)1.72K USD
FCF Margin—
FCF Yield-19.01%
Net Debt-6.26M USD
Net Debt/EBITDA0.38
Balance Sheet
Debt/Equity0.01
Current Ratio1.87
Quick Ratio1.67
Book Value/Sh0.5810 USD
Cash/Share0.5590 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)20.00 USD
Target Range15.00 USD – 25.00 USD
# Analysts2
Ownership
Shares Out.12.76M
Float8.61M
Insiders17.15%
Institutions14.23%
Short Interest
Short Ratio6.1d
Short % Float14.96%
Short % Out.14.91%
Shares Short1.90M
Short (prev mo.)1.74M
Technical
SMA 502.338 (+58.3%)
SMA 2003.276 (+12.9%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)280.44K
Avg Vol (10d)405.23K
Technical Indicators
RSI (14)68.5
MACD0.3209
MACD Signal0.2514
MACD Hist.+0.0694
BB Upper3.941 USD
BB Middle2.770 USD
BB Lower1.598 USD
BB Width84.60%
ATR (14)0.3272 USD
Vol Ratio (20d)0.27x